Literature DB >> 17397860

Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target.

Norbert Nagy1, Keisuke Shiroto, Gautam Malik, Chi-Kuang Huang, Mathias Gaestel, Maha Abdellatif, Arpad Tosaki, Nilanjana Maulik, Dipak K Das.   

Abstract

The existing literature indicates a crucial role of p38 MAP (mitogen-activated protein) kinase (p38MAPK) and its downstream target MAPKAP kinase 2 (MK2) in ischemic preconditioning (IPC). Accordingly, deletion of MK2 gene should abolish the cardioprotective ability of IPC. Interestingly, we were able to partially precondition the hearts from MK2(-/-) knockout mice suggesting the existence of an as yet unknown alternative downstream target of p38MAPK. A recent study from our laboratory also determined a crucial role of CREB (cyclic AMP response element binding protein) in IPC. Since CREB is a downstream target of MSK-1 (mitogen- and stress-activated protein kinase-1) situated at the crossroad of ERK (extracellular receptor kinase) and p38MAPK signaling pathways, we reasoned that MSK-1 could be a downstream molecular target for p38MAPK and ERK signaling in the IPC hearts. To test this hypothesis, the rat hearts were subjected to IPC by four cyclic episodes of 5 min ischemia and 10 min reperfusion. As expected, IPC induced the activation of ERK1/2, p38MAPK, MK2 and HSP (heat shock protein) 27 as evidenced by their increased phosphorylation; and the inhibition of p38MAPK with SB203580 almost completely, and the inhibition of ERK1/2 with PD098059 partially, abolished cardioprotective effects of IPC. Inhibition of MSK-1 with short hairpin RNA (shRNA) also abolished the IPC-induced cardioprotection. SB203580 partially blocked the effects of MSK-1 suggesting that MSK-1 sits downstream of p38MAPK. shRNA-MSK-1 blocked the contribution of both p38MAPK and ERK1/2 as it is uniquely situated at the downstream crossroad of both of these MAP kinases. Although MSK-1 sits downstream of both ERK1/2 and p38MAPK, ERK1/2 activation appears to play less significant role compared to p38MAPK, since its inhibition blocked MSK activation only partially. Consistent with these results, shRNA-MSK-1 blocked the partial PC in MK2(-/-) hearts, and in combination with SB203580, completely abolished the PC effects in the wild-type hearts. The IPC-induced survival signaling was almost completely inhibited with SB203580, and only partially with PD 098059 as evidenced from the inhibition patterns of IPC induced activation of CREB, Akt and Bcl-2. Again SB203580 alone or in combination with shRNA-MSK-1 inhibited IPC induced survival signal comparatively, suggesting that MSK-1 exists downstream of p38MAPK. Taken together, these results indicate for the first time MSK-1 as an alternative (other than MK2) downstream target for p38MAPK, which also transmits survival signal through the activation of CREB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17397860     DOI: 10.1016/j.yjmcc.2007.02.010

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  16 in total

1.  The roles of p38 MAPK/MSK1 signaling pathway in the neuroprotection of hypoxic postconditioning against transient global cerebral ischemia in adult rats.

Authors:  Pingping Zhu; Lixuan Zhan; Tingna Zhu; Donghai Liang; Jiaoyue Hu; Weiwen Sun; Qinghua Hou; Huarong Zhou; Baoxing Wu; Yanmei Wang; En Xu
Journal:  Mol Neurobiol       Date:  2013-12-19       Impact factor: 5.590

2.  Adenosine A(1) and A (3) receptor agonists reduce hypoxic injury through the involvement of P38 MAPK.

Authors:  D Leshem-Lev; E Hochhauser; B Chanyshev; A Isak; A Shainberg
Journal:  Mol Cell Biochem       Date:  2010-08-22       Impact factor: 3.396

3.  Participation of protein kinase C in the activation of Nrf2 signaling by ischemic preconditioning in the isolated rabbit heart.

Authors:  Xin Zhang; Zhibin Xiao; Jianmin Yao; Genshang Zhao; Xianen Fa; Jianli Niu
Journal:  Mol Cell Biochem       Date:  2012-09-26       Impact factor: 3.396

4.  Metformin mitigates apoptosis in ischemic myocardium.

Authors:  Nassrene Y Elmadhun; Ashraf A Sabe; Antonio D Lassaletta; Louis M Chu; Frank W Sellke
Journal:  J Surg Res       Date:  2014-05-17       Impact factor: 2.192

5.  Stretch-induced regulation of angiotensinogen gene expression in cardiac myocytes and fibroblasts: opposing roles of JNK1/2 and p38alpha MAP kinases.

Authors:  Hind Lal; Suresh K Verma; Honey B Golden; Donald M Foster; Manuela Smith; David E Dostal
Journal:  J Mol Cell Cardiol       Date:  2008-09-26       Impact factor: 5.000

Review 6.  Regulated production of free radicals by the mitochondrial electron transport chain: Cardiac ischemic preconditioning.

Authors:  Satoshi Matsuzaki; Pamela A Szweda; Luke I Szweda; Kenneth M Humphries
Journal:  Adv Drug Deliv Rev       Date:  2009-08-26       Impact factor: 15.470

7.  Hypoxia selectively activates the CREB family of transcription factors in the in vivo lung.

Authors:  Martin O Leonard; Katherine Howell; Stephen F Madden; Christine M Costello; Desmond G Higgins; Cormac T Taylor; Paul McLoughlin
Journal:  Am J Respir Crit Care Med       Date:  2008-08-08       Impact factor: 21.405

8.  The role of translational regulation in ultraviolet C light-induced cyclooxygenase-2 expression.

Authors:  Csaba F László; Sherine Fayad; Oliver L Carpenter; Kimberly S George; Wei Lu; Abir Adel Abdel-Razak Saad; Shiyong Wu
Journal:  Life Sci       Date:  2009-05-05       Impact factor: 5.037

9.  Cardioprotection with alpha-tocopheryl phosphate: amelioration of myocardial ischemia reperfusion injury is linked with its ability to generate a survival signal through Akt activation.

Authors:  Subhendu Mukherjee; Istvan Lekli; Manika Das; Angelo Azzi; Dipak K Das
Journal:  Biochim Biophys Acta       Date:  2008-05-22

10.  The Impact of Adenosine Fast Induction of Myocardial Arrest during CABG on Myocardial Expression of Apoptosis-Regulating Genes Bax and Bcl-2.

Authors:  Ahmed Shalaby; Timo Rinne; Otso Järvinen; Juha Latva-Hirvelä; Kristiina Nuutila; Antti Saraste; Jari Laurikka; Helena Porkkala; Pekka Saukko; Matti Tarkka
Journal:  Cardiol Res Pract       Date:  2009-12-22       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.